BICR in New Therapeutic Lung Cancer Trials

NCT05038826 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1833

Last updated 2023-03-14

No results posted yet for this study

Summary

Double reads in blinded independent central reviews (BICRs) are recommended to control the quality of trials but they are prone to discordances. We analyzed inter-reader discordances in a pool of lung cancer trials using RECIST 1.1.

Conditions

Sponsors & Collaborators

  • Median Technologies

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2021-08-10
Completion
2021-12-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05038826 on ClinicalTrials.gov